What is the next step in management for a patient with well‑controlled major depressive disorder on sertraline 200 mg daily, residual attention‑deficit/hyperactivity disorder symptoms, intermittent binge‑eating, and who has been taking atomoxetine (Strattera) 18 mg daily for two weeks?

Next Step: Increase Atomoxetine Dose to Therapeutic Target

After only 2 weeks at 18 mg daily, the patient has not yet reached the therapeutic dose range for atomoxetine (60–100 mg daily for adults), and atomoxetine requires 6–12 weeks at target dose to achieve full therapeutic effect—therefore, continue titrating atomoxetine upward before considering any medication changes or additions. 1

---

Rationale for Dose Optimization First

• Atomoxetine 18 mg daily is far below the evidence-based target dose of 60–100 mg daily (maximum 1.4 mg/kg/day or 100 mg/day, whichever is lower) required for ADHD symptom control in adults. 1
• Two weeks is insufficient to assess atomoxetine efficacy; this medication requires 6–12 weeks at therapeutic doses to reach full effect, unlike stimulants which work within days. 1
• Atomoxetine has medium-range effect sizes (approximately 0.7) compared to stimulants, making proper dosing critical to achieve any therapeutic benefit. 1

---

Recommended Titration Schedule

• Increase atomoxetine by 18–20 mg every 7–14 days until reaching 60 mg daily, then reassess after 2–4 weeks at that dose. 1
• If ADHD symptoms remain inadequately controlled at 60 mg after 4 weeks, titrate to 80 mg daily, then to 100 mg daily if needed. 1
• The typical effective dose range is 60–100 mg daily; most adults require at least 60 mg to see meaningful ADHD symptom reduction. 1

---

Why Atomoxetine Is Appropriate for This Patient

Depression Stability

• Depression is well controlled on sertraline 200 mg, and atomoxetine does not interfere with SSRI efficacy—there are no significant pharmacokinetic interactions between atomoxetine and sertraline. 1
• Sertraline can elevate serum atomoxetine levels through CYP2D6 inhibition, but this is manageable with standard dose titration and monitoring. 1

Binge Eating Considerations

• Atomoxetine is specifically recommended for ADHD with comorbid binge eating, as it may help reduce impulsive eating behaviors related to ADHD symptom dysregulation. 2
• Lisdexamfetamine (a stimulant) is FDA-approved for binge eating disorder and would be a reasonable alternative if atomoxetine fails, but atomoxetine should be optimized first given the patient's current stable psychiatric state. 2

Non-Stimulant Advantages

• Atomoxetine provides "around-the-clock" ADHD symptom coverage without the rebound effects or abuse potential of stimulants. 1
• Atomoxetine is not a controlled substance, simplifying prescription refills during long-term treatment. 3, 4

---

Monitoring During Titration

• Measure blood pressure and pulse at baseline and at each dose adjustment, as atomoxetine causes modest increases in cardiovascular parameters. 1
• Monitor for suicidality and clinical worsening, particularly during the first few months or at dose changes, as atomoxetine carries an FDA black box warning for increased suicidal ideation risk in children and adolescents (though risk is lower in adults). 1, 3
• Track appetite, weight, and sleep quality, as atomoxetine commonly causes decreased appetite and may cause somnolence or insomnia. 1, 3
• Assess ADHD symptom response using standardized rating scales (e.g., Adult ADHD Self-Report Scale) at 4-week intervals once therapeutic dose is reached. 1

---

When to Consider Switching or Adding Medications

If Atomoxetine Fails After Adequate Trial

• If ADHD symptoms remain inadequately controlled after 8–12 weeks at 80–100 mg daily, switch to a stimulant medication (methylphenidate or lisdexamfetamine) as first-line alternatives with 70–80% response rates. 1
• Stimulants work within days, allowing rapid assessment of ADHD response, and can be safely combined with sertraline without significant drug interactions. 1

If Binge Eating Worsens or Persists

• If binge eating remains problematic despite optimized atomoxetine and ADHD symptom control, consider switching to lisdexamfetamine, which is FDA-approved for both ADHD and binge eating disorder. 2
• Topiramate is an alternative for binge eating disorder but is not FDA-approved and has significant cognitive side effects that may worsen ADHD symptoms. 2

If Depression Destabilizes

• If depressive symptoms worsen during atomoxetine titration, continue sertraline and consider adding cognitive-behavioral therapy (CBT) rather than switching medications prematurely. 1
• Depression is not a contraindication to ADHD treatment; both conditions can and should be managed concurrently. 1

---

Common Pitfalls to Avoid

• Do not switch medications or add stimulants after only 2 weeks at a subtherapeutic atomoxetine dose—this is premature and denies the patient a fair trial of atomoxetine. 1
• Do not assume atomoxetine will treat both ADHD and depression; atomoxetine has no proven efficacy for depression despite its initial development as an antidepressant. 1
• Do not abruptly discontinue atomoxetine if switching to a stimulant; taper gradually to avoid discontinuation-emergent adverse events, though atomoxetine has a lower risk of withdrawal symptoms than SSRIs. 1, 3
• Do not prescribe bupropion as monotherapy for both ADHD and depression; no single antidepressant is proven effective for this dual purpose, and bupropion is a second-line agent for ADHD compared to stimulants or atomoxetine. 1

---

Alternative Approach: Switch to Stimulant Now

If the patient has severe functional impairment from ADHD symptoms and cannot wait 8–12 weeks for atomoxetine to reach full effect, switching to a stimulant (methylphenidate or lisdexamfetamine) is reasonable, as stimulants have 70–80% response rates and work within days. 1

• Stimulants can be safely combined with sertraline 200 mg without significant pharmacokinetic interactions. 1
• Depression is not a contraindication to stimulant therapy; both ADHD and depression can be treated concurrently. 1
• If binge eating is a primary concern, lisdexamfetamine is FDA-approved for both ADHD and binge eating disorder and would be the preferred stimulant choice. 2

However, given that depression is well controlled and the patient has only been on atomoxetine for 2 weeks at a subtherapeutic dose, optimizing atomoxetine first is the most evidence-based approach before introducing a controlled substance. 1, 3